Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04733547
Other study ID # CR-21-007
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 22, 2021
Est. completion date November 29, 2023

Study information

Verified date December 2023
Source Daegu Catholic University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The use of central venous pressure has been abandoned for the assessment of intravascular volume status. The dynamic fluctuation of central venous pressure according to heart rate is quantitatively measured by spectral analysis of the central venous pressure waveform. Its clinical utility in the assessment of intravascular volume status is investigated.


Description:

The use of central venous pressure, which is one of the static preload indices, has been abandoned for the assessment of intravascular volume status because of its unreliability. The static preload indices have been replaced with dynamic preload indices, such as stroke volume variation or pulse pressure variation because the dynamic preload indices reliably predict fluid responsiveness and perform better than the static preload indices. However, the periodic component of central venous pressure, which goes with cardiac cycles, has not been investigated. The power corresponding to heart rate from spectral analysis of central venous pressure waveform represents the extent of the dynamic fluctuation of central venous pressure and is assumed to reflect intravascular volume status. It is hypothesized that the spectral power of central venous pressure corresponding to heart rate represents intravascular volume status.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 29, 2023
Est. primary completion date November 29, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: - American Society of Anesthesiologists physical status 1 - Scheduled for donor hepatectomy under general anesthesia Exclusion Criteria: - Arrhythmia - Valvular heart disease - Coronary artery disease - Cerebrovascular disease - Hypertension - Diabetes mellitus - Renal insufficiency - Pulmonary problems - Any type of liver disease - Body mass index greater than 35 kg/m2 - Human immunodeficiency virus infection - Psychosocial problems - Electrolyte imbalance - Reoperation

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Placement of a central venous catheter
The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
Device:
Monitoring of central venous pressure
Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
Drug:
Furosemide-induced hypovolemia before graft procurement
Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is <1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces >1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
Replacement of fluid loss after graft procurement
Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
Device:
Monitoring of stroke volume variation
Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.

Locations

Country Name City State
Korea, Republic of Daegu Catholic University Medical Center Daegu

Sponsors (1)

Lead Sponsor Collaborator
JongHae Kim

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (4)

Alian AA, Galante NJ, Stachenfeld NS, Silverman DG, Shelley KH. Impact of lower body negative pressure induced hypovolemia on peripheral venous pressure waveform parameters in healthy volunteers. Physiol Meas. 2014 Jul;35(7):1509-20. doi: 10.1088/0967-3334/35/7/1509. Epub 2014 Jun 5. — View Citation

Hocking KM, Alvis BD, Baudenbacher F, Boyer R, Brophy CM, Beer I, Eagle S. Peripheral i.v. analysis (PIVA) of venous waveforms for volume assessment in patients undergoing haemodialysis. Br J Anaesth. 2017 Dec 1;119(6):1135-1140. doi: 10.1093/bja/aex271. — View Citation

Hocking KM, Sileshi B, Baudenbacher FJ, Boyer RB, Kohorst KL, Brophy CM, Eagle SS. Peripheral Venous Waveform Analysis for Detecting Hemorrhage and Iatrogenic Volume Overload in a Porcine Model. Shock. 2016 Oct;46(4):447-52. doi: 10.1097/SHK.0000000000000615. — View Citation

Sileshi B, Hocking KM, Boyer RB, Baudenbacher FJ, Kohurst KL, Brophy CM, Eagle S. Peripheral venous waveform analysis for detecting early hemorrhage: a pilot study. Intensive Care Med. 2015 Jun;41(6):1147-8. doi: 10.1007/s00134-015-3787-0. Epub 2015 Apr 11. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Age Age at the time of surgery On arrival at the operating room
Other Sex Biological sex On arrival at the operating room
Other Height Measured in cm The day before surgery
Other Weight Measured in kg The day before surgery
Other Aspartate transaminase Measured in U/L The day before surgery
Other Alanine transaminase Measured in U/L The day before surgery
Other Blood urea nitrogen Measured in mg/dl The day before surgery
Other Creatinine Measured in mg/dl The day before surgery
Other Serum sodium level Measured in mmol/L The day before surgery
Other Serum potassium level Measured in mmol/L The day before surgery
Other Serum chloride level Measured in mmol/L The day before surgery
Other Graft weight Measured in gram At graft procurement
Other Total amount of fluids The total volume of colloids and crystalloids administered throughout the entire surgery At the end of surgery
Other Aspartate transaminase Measured in U/L 1 hour after surgery
Other Alanine transaminase Measured in U/L 1 hour after surgery
Other Blood urea nitrogen Measured in mg/dl 1 hour after surgery
Other Creatinine Measured in mg/dl 1 hour after surgery
Other Serum sodium level Measured in mmol/L 1 hour after surgery
Other Serum potassium level Measured in mmol/L 1 hour after surgery
Other Serum chloride Measured in mmol/L 1 hour after surgery
Primary Spectral power of central venous pressure corresponding to heart rate during 5 minutes before graft procurement A band-pass filter (0.15-3 Hz) is applied to the 5 minute-long segment. The 5 minute-long segments are divided into 100 second-long segments overlapping 50% with each adjacent segment. Each segment is submitted to fast Fourier transformation. The spectral powers obtained from the periodograms of each segment are averaged. The integrated area corresponding to heart rate is the spectral power corresponding to heart rate. During 5 minutes before graft procurement
Secondary Spectral powers of central venous pressure corresponding to respiratory rate and heart rate during 5 minutes before the first dose of furosemide A band-pass filter (0.15-3 Hz) is applied to the 5 minute-long segment. The 5 minute-long segments are divided into 100 second-long segments overlapping 50% with each adjacent segment. Each segment is submitted to fast Fourier transformation. The spectral powers obtained from the periodograms of each segment are averaged. The integrated areas corresponding to respiratory rate and heart rate are the spectral powers corresponding to respiratory rate and heart rate. During 5 minutes before the first dose of furosemide
Secondary Spectral powers of central venous pressure corresponding to respiratory rate and heart rate between 30 and 35 minutes after surgical incision A band-pass filter (0.15-3 Hz) is applied to the 5 minute-long segment. The 5 minute-long segments are divided into 100 second-long segments overlapping 50% with each adjacent segment. Each segment is submitted to fast Fourier transformation. The spectral powers obtained from the periodograms of each segment are averaged. The integrated areas corresponding to respiratory rate and heart rate are the spectral powers corresponding to respiratory rate and heart rate. Between 30 and 35 minutes after surgical incision
Secondary Spectral power of central venous pressure corresponding to respiratory rate during 5 minutes before graft procurement A band-pass filter (0.15-3 Hz) is applied to the 5 minute-long segment. The 5 minute-long segments are divided into 100 second-long segments overlapping 50% with each adjacent segment. Each segment is submitted to fast Fourier transformation. The spectral powers obtained from the periodograms of each segment are averaged. The integrated area corresponding to respiratory rate is the spectral power corresponding to respiratory rate. During 5 minutes before graft procurement
Secondary Spectral powers of central venous pressure corresponding to respiratory rate and heart rate during 5 minutes after administration of 6% hydroxyethyl starch A band-pass filter (0.15-3 Hz) is applied to the 5 minute-long segment. The 5 minute-long segments are divided into 100 second-long segments overlapping 50% with each adjacent segment. Each segment is submitted to fast Fourier transformation. The spectral powers obtained from the periodograms of each segment are averaged. The integrated areas corresponding to respiratory rate and heart rate are the spectral powers corresponding to respiratory rate and heart rate. During 5 minutes after administration of 6% hydroxyethyl starch
Secondary Stroke volume variation during 5 minutes before the first dose of furosemide The median of the values calculated at a 20-second interval During 5 minutes before the first dose of furosemide
Secondary Stroke volume index during 5 minutes before the first dose of furosemide The median of the values calculated at a 20-second interval During 5 minutes before the first dose of furosemide
Secondary Cardiac index during 5 minutes before the first dose of furosemide The median of the values calculated at a 20-second interval During 5 minutes before the first dose of furosemide
Secondary Stroke volume variation between 30 and 35 minutes after surgical incision The median of the values calculated at a 20-second interval Between 30 and 35 minutes after surgical incision
Secondary Stroke volume index between 30 and 35 minutes after surgical incision The median of the values calculated at a 20-second interval Between 30 and 35 minutes after surgical incision
Secondary Cardiac index between 30 and 35 minutes after surgical incision The median of the values calculated at a 20-second interval Between 30 and 35 minutes after surgical incision
Secondary Stroke volume variation during 5 minutes before graft procurement The median of the values calculated at a 20-second interval During 5 minutes before graft procurement
Secondary Stroke volume index during 5 minutes before graft procurement The median of the values calculated at a 20-second interval During 5 minutes before graft procurement
Secondary Cardiac index during 5 minutes before graft procurement The median of the values calculated at a 20-second interval During 5 minutes before graft procurement
Secondary Stroke volume variation during 5 minutes after administration of 6% hydroxyethyl starch The median of the values calculated at a 20-second interval During 5 minutes after administration of 6% hydroxyethyl starch
Secondary Stroke volume index during 5 minutes after administration of 6% hydroxyethyl starch The median of the values calculated at a 20-second interval During 5 minutes after administration of 6% hydroxyethyl starch
Secondary Cardiac index during 5 minutes after administration of 6% hydroxyethyl starch The median of the values calculated at a 20-second interval During 5 minutes after administration of 6% hydroxyethyl starch
Secondary Total dose of furosemide The total dose of furosemide used for the promotion of diuresis At graft procurement
Secondary Urine output at graft procurement The total amount of urine output between the placement of urinary catheter and graft procurement At graft procurement
Secondary Total urine output at the end of surgery The total amount of urine output at the end of surgery At the end of surgery
Secondary Intraoperative blood loss Calculated as blood loss (ml) = [estimated blood volume*(preoperative hematocrit-postoperative hematocrit)]/mean between the 2 hematocrit values, where estimated blood volume (ml) = weight(kg)^0.425*height(cm)^0.725*0.007184*2217+age(years)*1.06 for female and weight(kg)^0.425*height(cm)^0.725*0.007184*3064-825 for male 1 day after surgery
See also
  Status Clinical Trial Phase
Suspended NCT02315937 - Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography' N/A
Active, not recruiting NCT01681238 - Goal-directed Therapy in High-risk Surgery N/A
Completed NCT01210417 - Trauma Heart to Arm Time N/A
Recruiting NCT05557461 - Assessment of Fluid Responsiveness in Septic Shock Patients, Can End-tidal co2 Measurement Help?
Withdrawn NCT03246425 - Influence of Mechanical Ventilation Mode on Arterial Pressure Variations- a Pilot Study N/A
Completed NCT02721654 - Plasma-Lyte 148® versUs Saline Study Phase 4
Completed NCT02903316 - Predicting Fluid Responsiveness in on Pump Coronary Artery Bypass Graft Using Extra Systoles N/A
Completed NCT03009305 - Cerebral Oximetry in Lower Body Negative Pressure N/A
Completed NCT01456559 - Detection of Hypovolemia Using Pleth Variability Index (PVI) N/A
Completed NCT00380107 - Volume Deficit Prior to Surgery Phase 4
Recruiting NCT06123039 - Use of Heart-lung Interaction to Predict Haemodynamic Tolerance to the Open Lung Approach With Individualised PEEP
Completed NCT04573842 - Ultrasound Assessment of the Subclavian Vein for Predicting Hypotension in Children After Anaesthesia Induction
Completed NCT05150418 - Supplemental Oxygen in Hypovolemia Phase 1
Completed NCT02961439 - Validation of Epworth Richmond's Echocardiography Education Focused Year N/A
Completed NCT01535703 - Comparison of Cardiac Output Measurement Between Transpulmonary Thermodilution and Photoplethysmography N/A
Completed NCT01010022 - Trial of 6% HES130/0.4 Phase 3
Completed NCT04641949 - Methoxyflurane and Fentanyl in LBNP Phase 4
Recruiting NCT03592290 - Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia
Suspended NCT03736421 - Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients
Completed NCT02679625 - Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients